# Frontier Medicines

> Frontier Medicines is a precision-medicine biotech using chemoproteomics, covalent chemistry, and machine learning to drug proteins long considered 'undruggable.' Its lead candidate, FMC-376, is a first-in-class dual ON/OFF inhibitor of KRAS G12C now in the Phase 1/2 PROSPER trial. Backed by $315M+ in venture funding and a major AbbVie partnership, the company is one of the most-watched names in next-generation targeted cancer therapy.

- **Founded:** 2018
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Chris Varma (Co-founder & CEO), Daniel Nomura (Co-founder & Scientific Advisor (UC Berkeley)), Roberto Zoncu (Co-founder & Scientific Advisor (UC Berkeley))
- **Team size:** ~77 employees
- **Products:** Frontier Platform, FMC-376, Targeted Protein Degradation Pipeline
- **Notable:** First-in-class dual ON/OFF KRAS G12C inhibitor (FMC-376) cleared IND and dosed first patient in Phase 1/2 PROSPER trial., Raised $315.5M+ in total funding across Seed, A, B, and C rounds., Signed AbbVie partnership worth >$1B in potential milestones (2020).

## Products & services

- **Frontier Platform** — Proprietary chemoproteomics-powered drug discovery engine combining covalent fragment libraries, mass spectrometry, structural methods, and machine learning to identify ligandable sites across the proteome.
- **FMC-376** — Lead clinical candidate - a first-in-class dual inhibitor of both the ON and OFF states of KRAS G12C, designed to overcome resistance seen with single-state inhibitors. In Phase 1/2 PROSPER trial.
- **Targeted Protein Degradation Pipeline** — Preclinical programs leveraging novel E3 ligases to degrade undruggable oncology and immunology targets.

## Achievements

- First-in-class dual ON/OFF KRAS G12C inhibitor (FMC-376) cleared IND and dosed first patient in Phase 1/2 PROSPER trial.
- Raised $315.5M+ in total funding across Seed, A, B, and C rounds.
- Signed AbbVie partnership worth >$1B in potential milestones (2020).
- Built proprietary chemoproteomics platform spanning covalent fragment screening, MS, structural biology, and ML.
- Appointed biotech veteran Gerardo Ubaghs as CFO (2024).

## Latest updates

- **2024-06** — Announced $20M Series C extension and appointment of Gerardo Ubaghs as CFO.
- **2024-02** — Closed oversubscribed $80M Series C co-led by Deerfield and Droia, with Galapagos as a strategic investor.
- **2024** — First participant dosed in the Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C cancers.
- **2023** — Announced milestone payment from AbbVie partnership tied to advancement of lead candidates against a historically undruggable transcription factor.

## Links

- Website: https://frontiermeds.com
- LinkedIn: https://www.linkedin.com/company/frontier-medicines
- Twitter/X: https://twitter.com/frontiermeds

---

Profile page: https://yespress.io/frontier-medicines
Published by YesPress — https://yespress.io
Last updated: 2026-05-19